Background Pepsinogens are proenzymes secreted by gastric chief cells. In humans, their serum concentrations reflect gastric mucosal morphological and functional status. Objectives To evaluate serum canine pepsinogen-A (cPG-A), C-reactive protein (CRP), and canine pancreatic lipase immunoreactivity (cPLI) concentrations in dogs with gastric dilatation-volvulus (GDV). Animals Sixty-six dogs presented with GDV and 79 healthy controls. Methods Blood was collected prospectively, and records retrospectively reviewed. Results Median cPG-A concentration was higher in GDV dogs (median, 397 μg/L; range, 37–5,410) compared to controls (median, cPG-A 304 μg/L; range, 18–848; P = .07). Mortality rate in GDV dogs was 22.7%. In nonsurvivors of GDV, median cPG-A was higher compared to survivors (median, 746 μg/L; range, 128–5,409 versus median, 346; range, 36–1,575, respectively; P = .003). The proportion of dogs with increased cPG-A increased with gastric wall damage score (P = .007). An ROC analysis of cPG-A as a predictor of death showed an area under the curve (AUC) of 0.75, higher than lactate (AUC 0.66), and corresponded to a sensitivity and specificity of 53% and 88%, respectively. CRP was increased in 48 dogs (75%), cPLI was >200 μg/L in 26 dogs (39.4%) and >400 μg/L in 12 dogs (18.2%) but both analytes had no association with outcome. Conclusions Presurgical cPG-A concentration was positively and significantly associated with gastric wall lesion severity, but, based on ROC analysis, it was only a moderate outcome predictor. CRP and cPLI were commonly increased in dogs with GDV.

Eosinophils play a crucial role in the inflammatory response in conjunction with both innate and adaptive immunity. Eosinophils have long been recognized as inflammatory leukocytes that are particularly important in patients with parasitic infestations. However, recent studies in veterinary medicine demonstrate a number of canine eosinophilic gastrointestinal (GI) disorders unrelated to a parasitic infestation. Although the underlying pathophysiology behind eosinophilic infiltration of the canine GI tract remains uncertain, medical intervention aiming to decrease the activation of eosinophils seems effective in reducing symptoms and preventing organ damage. This review focuses on the biology of eosinophils and their products. It describes, the composition of eosinophil granules, mechanisms of eosinophil activation, and eosinophil-related disease processes leading to organ damage. Even though the main clinical signs of canine eosinophilic gastroenteritis, vomiting and diarrhea, are similar to those of other types of gastroenteritis, the clinical response and prognosis are worse for this condition. The clinical signs and diagnostic approach for eosinophilic GI disorders are described and compared between canine and human patients for each region of GI tract, from the esophagus to the colon. Moreover, the current treatments for this syndrome in canine and human patients are summarized and paralleled. The comparative study of canine and human patients with eosinophilic gastroenteritis will advance the understanding of this syndrome in both species and may lead to the development of novel treatment strategies.

The clinical usefulness of serum 3-BrY concentrations for subclassifying dogs with food-responsive diarrhea (FRD) and steroid-responsive diarrhea (SRD) has not been studied. To compare serum 3-BrY concentrations in dogs with FRD, dogs with SRD, and healthy control dogs. 38 dogs with FRD, 14 dogs with SRD, and 46 healthy dogs. Prospective study. Measurement of 3-BrY concentration in serum samples was performed by gas chromatography/mass spectrometry. There was no association of peripheral eosinophilia in dogs with FRD, SRD, and healthy control dogs (P = 0.069). There was no significant correlation between peripheral eosinophil counts and serum 3-BrY concentrations (ρ = −0.15, P = 0.13). Serum 3-BrY concentrations in dogs with SRD (median [range] = 3.27, 0.9–26.23 μmol/L) were significantly higher than in dogs with FRD (median [range] = 0.99, 0.62–8.82 μmol/L; P = 0.007) or in healthy dogs (median [range] = 0.62, 0.62–1.79 μmol/L; P < 0.001). Also, serum 3-BrY concentrations in dogs with FRD were significantly higher than in healthy dogs (P = 0.025). There was no significant correlation between the canine chronic enteropathy clinical activity index and serum 3-BrY concentrations (ρ = 0.17, P = 0.23). Measurement of serum 3-BrY concentrations, but not the peripheral eosinophil count, is helpful for detecting dogs with SRD and FRD.

Background and Aim: Long-haired cats may have an increased risk of dermatophytosis due to insufficient grooming and their thick hair coat trapping fungal spores. The prevalence of subclinical dermatophytosis in long-haired cats was evaluated using fungal culture and Wood's lamp test. Hematology and blood chemistry results were compared between cats negative and positive for dermatophytosis. Materials and Methods: A total of 127 cats (median age, 3 years [range, 10 months-10 years]) without feline leukemia virus or feline immunodeficiency virus infection were classified into short-haired (n=64) and long-haired (n=63) groups. Hair samples were cultured on a fungal culture medium (dermatophyte test medium, enhanced sporulation agar, and Sabouraud agar). Results: The prevalence of dermatophytosis in short-haired and long-haired cats was 6.25% (95% confidence interval [CI], 2.15-12.28) and 34.92% (95% CI, 22.94-46.90), respectively. The odds of long-haired cats having dermatophytosis were 8.05 (95% CI, 2.44-33.97) times greater than that in short-haired cats. The number of positive dermatophytosis found in domestic short-haired cats (2/50, 4.0%) was significantly lower than that in Persian cats (17/47, 36.17%; p<0.001) and long-haired mixed breed cats (3/7, 42.86%; p=0.011). The overall sensitivity and specificity of the Wood's lamp test for diagnosing Microsporum canis infection were 37.5% (95% CI, 21.2-57.3%) and 96.1% (95% CI, 90.4-98.5%), respectively. Cats with dermatophytosis had significantly lower hematocrit and serum albumin levels than cats without dermatophytosis. Conclusion: Subclinical dermatophytosis was more common in long-haired cats; therefore, dermatophyte examinations should be performed routinely.

The objective of this study was to evaluate the effect of the COP chemotherapeutic protocol on hematological parameters, CD4⁺/CD8⁺ ratio, and the mortality of 18 client-owned FeLV-infected cats with mediastinal lymphoma. The complete blood count, creatinine, alanine aminotransferase, and CD4⁺/CD8⁺ ratio were measured four times before treating with chemotherapy in the 1st, 2nd, 3rd, and 4th weeks. The white blood cell (WBC) counts at the 1st week were significantly different from the 2nd, 3rd, and 4th inductions (p = 0.0075, p = <0.0001, and p = 0.0271, respectively). The neutrophils at the 1st week were significantly different from the 2nd and 3rd inductions (p = 0.0179, and p < 0.0001, respectively). The packed cell volume (PCV) at the 1st week was significantly differed from the 2nd, 3rd, and 4th induction times (p = 0.0029, p = 0.0006, and p = 0.0029, respectively. The mean corpuscular volume (MCV) at the 1st week was significantly different from the 4th week (p = 0.0145). We found that chemotherapy did not cause any significant change in the CD4⁺/CD8⁺ ratio (p-value 0.7407). The Kaplan–Meier curves showed the median survival time (MST) for the cats with a CD4⁺/CD8 ratio of less than 1 after the 1st week of chemotherapy was 134 days. This suggested that COP chemotherapy was a safe treatment for FeLV-infected cats with mediastinal lymphoma.

3-Bromotyrosine (3-BrY) is a stable product of eosinophil peroxidase and may serve as a marker of eosinophil activation. A gas chromatography/mass spectrometry method to measure 3-BrY concentrations in serum from dogs has recently been established and analytically validated. The aims of this study were to determine the stability of 3-BrY in serum, to determine the association between peripheral eosinophil counts and the presence of an eosinophilic infiltrate in the gastrointestinal tract, and to compare serum 3-BrY concentrations in healthy dogs (n = 52) and dogs with eosinophilic gastroenteritis (EGE; n = 27), lymphocytic-plasmacytic enteritis (LPE; n = 25), exocrine pancreatic insufficiency (EPI; n = 26), or pancreatitis (n = 27). Serum 3-BrY concentrations were stable for up to 8, 30, and 180 days at 4°C, −20°C, and −80°C, respectively. There was no significant association between peripheral eosinophil count and the presence of eosinophils in the GI tissues (P = 0.1733). Serum 3-BrY concentrations were significantly higher in dogs with EGE (median [range] = 5.04 [≤0.63-26.26] μmol/L), LPE (median [range] = 3.60 [≤0.63-15.67] μmol/L), and pancreatitis (median [range] = 1.49 [≤0.63-4.46] μmol/L) than in healthy control dogs (median [range] = ≤0.63 [≤0.63-1.79] μmol/L; P < 0.0001), whereas concentrations in dogs with EPI (median [range] = 0.73 [≤0.63-4.59] μmol/L) were not different compared to healthy control dogs. The present study revealed that 3-BrY concentrations were stable in serum when refrigerated and frozen. No relationship between peripheral eosinophil count and the presence of eosinophils infiltration in the GI tissues was found in this study. In addition, serum 3-BrY concentrations were increased in dogs with EGE, but also in dogs with LPE and pancreatitis. Further studies are needed to determine whether measurement of 3-BrY concentrations in serum may be useful to assess patients with suspected or confirmed EGE or LPE.